newsfilter
← Latest News
GlobeNewswire·

Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor WALTHAM, Mass., Oct. 10,